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“A menos que modifiquemos a nossa 
maneira de pensar, não seremos 
capazes de resolver os problemas 
causados pela forma como nos 
acostumamos a ver o mundo”.  
 
(Albert Einstein) 
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Resumo 
A metanfetamina (Meth) é um psicostimulante altamente viciante que 
causa graves consequências à saúde e que produz efeitos neurotóxicos a longo 
prazo. As células da microglia, macrófagos residentes do sistema nervoso central 
(SNC), desempenham um papel crucial nos processos inflamatórios. Uma vez 
activada, a microglia segrega uma variedade de moléculas, incluindo citocinas 
pró-inflamatórias, óxido nítrico e superóxido, que podem causar danos 
oxidativos no tecido neuronal. Recentemente, a microglia tem vindo a ser 
considerada como mediador da neurotoxicidade induzida pela Meth. Além disso, 
tem sido descrito que Meth induz activação das células da microglia no cérebro 
de consumidores humanos.  
Neste estudo, investigámos os efeitos da Meth nas células da microglia e 
nos astrócitos, tal como na intercomunicação entre estes dois tipos de células. De 
forma a obter maior conhecimento sobre a activação da micróglia, analisamos os 
efeitos deste psicostimulante em culturas primárias de microglia através de 
marcadores pró- e anti-inflamatórios utilizando imunocitoquímica, microscopia de 
fluorescência quantitativa e RT-PCR quantitativo. Mostramos que a Meth não 
induz uma assinatura nem pró- nem anti-inflamatória na microglia. Estudámos 
também os efeitos da Meth em culturas primárias de astrócitos através de 
marcadores de reactividade (F-actina, GFAP e iNOS). Os nossos resultados 
demonstram que Meth não induz astrogliose in vitro. Na tentativa de esclarecer 
de que forma a Meth poderia afectar a intercomunicação entre as células da 
microglia e os astrócitos, avaliámos o efeito do meio condicionado de astrócitos 
(ACM) tratados com Meth na microglia. Verificamos que este ACM altera o perfil 
da microglia promovendo uma assinatura pró-inflamatória, verificando-se um 
aumento significativo  da actividade fagocitária, produção de espécies reactivas 
de oxigénio e expressão da iNOS comparativamente com células incubadas com 
meio condicionado de astrócitos não tratados. Em suma, aqui demonstramos que 
Meth, por si só não induz nem um perfil pró- nem anti-inflamatório em células da 
microglia cortical. A Meth também não aumenta a reactividade dos astrócitos em 
cultura. No entanto, a activação da microglia induzida pela Meth aparece ser 
mediada por factores solúveis libertados pelos astrócitos tratados com Meth, 
sugerindo que Meth induz a activação da microglia de uma forma dependente 
dos astrócitos. 
vi 
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Abstract 
Methamphetamine (Meth) is a highly addictive psychostimulant posing 
severe health consequences and long-term neurotoxic effects. Microglial cells, the 
resident macrophages of the central nervous system (CNS), play crucial roles in 
inflammatory processes. Upon activation, microglia secrete an array of molecules 
including pro-inflammatory cytokines, nitric oxide and superoxide, which can 
cause oxidative damage to the neuronal tissue. Recently, microglia have been 
implicated as mediators of Meth-induced neurotoxicity. Besides, it has been 
described that Meth induces microglial cell activation in the brain of human 
abusers.  
In this study, we investigated the effects of Meth in microglial cells and 
astrocytes, as well as the crosstalk between these two cell types. To gain further 
insight into microglia activation we analyzed the effects of this psychostimulant 
in pro- and anti-inflammatory markers in primary cortical microglial cell cultures 
using immunocytochemistry, quantitative fluorescence microscopy and 
quantitative RT-PCR. We show that Meth triggered neither a pro-inflammatory nor 
an anti-inflammatory signature in microglia. We also studied the effects of Meth 
on primary astrocyte cultures using reactivity markers (f-actin, GFAP and iNOS). 
Our results demonstrate that Meth did not trigger astrogliosis in vitro. Moreover, 
in an attempt to clarify how Meth could affect the crosstalk between microglial 
cells and astrocytes, the effect of conditioned media from astrocytes (ACM) 
treated with Meth was evaluated on microglia. We found that ACM treated with 
Meth shifted microglia profile to a pro-inflammatory signature significantly 
increasing in their phagocytic activity, reactive oxygen species production and 
iNOS expression when compared to cells incubated with conditioned media from 
naïve astrocytes. Overall, here we describe that Meth per se does not trigger 
neither a pro nor an anti-inflammatory signature in cortical microglial cells. 
Likewise, Meth does not increase the reactivity of cultured astrocytes as well. 
Nonetheless, Meth-induced microglia activation appears to be mediated by 
soluble factors released from Meth-sensitized astrocytes, suggesting that Meth 
induces microglial activation in an astrocyte-dependent fashion. 
 
Keywords: Astrocyte conditioned medium; Astrocyte; Methamphetamine; 
Microglia; Pro-inflammatory signature.  
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1 Overview 
1.1 Methamphetamine 
Methamphetamine (Meth) is an illegal psychostimulant drug that is widely 
abused all over the world. It belongs to the group of amphetamines and it is 
estimated that there are about 14 to 52 million users worldwide (Granado, Ares-
Santos et al. 2013). Meth is the second most consumed drug of abuse after 
cannabis and presents a higher consumption rate in young-aged groups, 
(Krasnova and Cadet 2009)  which establishes Meth consumption to be 
considered a significant public health problem in several countries (Karila, 
Weinstein et al. 2010). 
The Japanese scientist Nagai Nagayoshi first synthesized Meth from 
ephedrine in 1893, six years after the synthesis of amphetamine (Anglin, Burke et 
al. 2000, Panenka, Procyshyn et al. 2013). The chemical structure of Meth (N-
methyl-O-phenylisopropylamine) comprehends a phenyl ring connected to an 
amino group by two-carbon side chain with a methyl group on carbon-1 of the 
side chain (Fleckenstein, Volz et al. 2007, Huang, Wu et al. 2009, Krasnova and 
Cadet 2009). There are two enantiomers of this compound, D-Methamphetamine 
and L-Methamphetamine (Fig.1). The D-Methamphetamine is the most powerful 
and is the form manufactured for illicit use (Petit, Karila et al. 2012).  
 
 
 
Figure 1. Chemical structure of Meth isomers: D- Methamphetamine and L-
Methamphetamine (adapted from http://www.sigmaaldrich.com/technical-documents/articles 
/analytical/bioanalytical/chiral-lcms-methamphetamine.html). 
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This illicit drug, also called ice, Meth, crank, jib, speed or crystal, is 
available in different forms such as a pure crystalline hydrochloride salt or as 
formulated tablets. Meth is soluble in water, and may be administered by 
intranasal sniffing, pulmonary inhalation, injection and oral ingestion (Karila, 
Weinstein et al. 2010, Granado, Ares-Santos et al. 2013, Panenka, Procyshyn et al. 
2013). Acute use of Meth leads to euphoria, increased vigilance, cardiovascular 
changes, hyperactivity, hypersexuality, decreased anxiety and increased energy. 
Chronic abuse of this psychostimulant can, however, result in adverse 
physiological and neurological disorders, including weight and muscular loss, 
accelerated aging, brain injury, cognitive impairment, mood disturbances and 
psychomotor dysfunction. Meth symptoms may persist for several hours due to 
its half-life, which is about 10 to 12 hours (Krasnova and Cadet 2009). 
1.1.1 Neurotoxicity 
Meth consumption leads to neuropsychiatric and neurotoxic impairment in 
humans. Meth is lipophilic, which allows the compound to rapidly cross the 
blood-brain barrier (BBB). In the brain, Meth leads to an impairment of the 
monoaminergic system (dopamine, serotonin and norepinephrine), BBB 
breakdown, glutamate release, overproduction of free radicals, mitochondrial 
dysfunction and neuroimflammation that all-together contribute for neuronal cell 
death and neurotoxicity (Huang, Wu et al. 2009). 
1.1.1.1 Blood Brain Barrier dysfunctions 
Several studies examining the effects of Meth on the BBB function have 
shown that it leads to the breakdown of the BBB. Such effect has been established 
as one of the most prominent events of Meth toxicity (Sharma and Ali 2006). In 
rodents, it has been shown that Meth leads to BBB damage in the cortex, 
hippocampus, thalamus, hypothalamus, cerebellum and amygdala (Bowyer and 
Ali 2006, Kiyatkin, Brown et al. 2007, Krasnova and Cadet 2009, Sharma and 
Kiyatkin 2009). 
 In line with this, some studies suggested that neurotoxic effects induced 
by Meth such as hyperthermia, ROS production and neuroimflammation lead to 
an increase in BBB permeability (Ramirez, Potula et al. 2009). Oxidative stress and 
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cytokines production seem to be a possible mediator of BBB breakdown, since 
these molecules may modify tight junction function and extracellular matrix 
remodelling, which leads to the impairment of endothelial cells form the BBB 
(Yamamoto, Moszczynska et al. 2010).  
1.1.1.2 Dopaminergic system dysfunction 
 Dopamine (DA) is an important neurotransmitter that modulates 
locomotion, motivation, cognition and reward-associated functions. Dopaminergic 
dysfunction has been implicated in several pathologies such as Parkinson, 
Schizophrenia, bipolar disorder, attention deficits, hyperactivity and drug 
addiction (Saha, Sambo et al. 2014). Under normal conditions, DA is released into 
the synaptic cleft in response to neuronal activity. When stimuli cease, DA is 
taken up through dopamine transporters (DAT), which are located at the plasma 
membrane of the pre-synaptic neuron. Once inside the neuron, DA is stored into 
vesicles by vesicular monoamine transporter (VMAT), which protects DA from 
oxidation (Krasnova and Cadet 2009). 
 Due to the structural similarity between Meth and DA (Fig.2), Meth can 
enter dopaminergic neurons via DAT, by acting as a competitive inhibitor for DA 
re-uptake, leading to DA accumulation in the synaptic cleft. Such mechanistic 
route seems to be important for Meth toxicology as DAT-knockout mice are 
resistant to the persistent dopaminergic deficits produced by Meth administration 
(Volz, Hanson et al. 2007).  
 
 
 
 
 
 
 
 
Figure 2.  Chemical structure of DA (Dopamine) and Meth (Methamphetamine). Adapted 
from (Hart, Marvin et al. 2011). 
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Meth lipophilic diffusion across neuronal membranes as also been 
described (Saha, Sambo et al. 2014). Once inside the cell, Meth promotes 
cytoplasmatic accumulation of monoamines, which would be stored in synaptic 
vesicles, via the inhibition of VMAT. While such effect causes a rapid depletion of 
DA from synaptic vesicles (Volz, Hanson et al. 2007, Krasnova and Cadet 2009), 
this accumulation in the cytosol leads to an increased metabolism of DA by 
monoamine oxidase A (MAO-A), resulting in the production of high amounts of 
H
2
O
2
 and other reactive oxygen species (ROS; Fig.3). Moreover, DA is also 
oxidized forming reactive quinones, which modifies lipids and proteins at  
neuronal membranes, further increasing the formation of ROS (Brown and 
Yamamoto 2003). Besides, Meth inhibits the expression of tyrosine hydroxylase 
(TH), an essential enzyme for dopamine biosynthesis (Thomas and Kuhn 2005). 
Taken together, these studies show that Meth leads to a complete disruption of 
cellular DA homeostasis in the dopaminergic neuron. 
 
 
 
 
 
Figure 3. Mechanisms whereby Meth causes dopaminergic system dysfunction: DA, 
dopamine; DAT, dopamine transporters; MAO, monoamine oxidase; VMAT-2, vesicular monoamine 
transporter; METH, methamphetamine; DOPAC, 3,4-Dihydroxyphenylacetic acid; RE, endoplasmic 
reticulum; L-DOPA, L-3,4-dihydroxyphenylalanine. Adapted from (Krasnova and Cadet 2009).  
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1.1.1.3 Mitochondrial dysfunction 
Due to its lipophilic properties, Meth penetrates and accumulates in the 
mitochondria. Such accumulation of positively charged molecules disrupt the 
electrochemical gradient established by the oxidative phosphorylation, impairing 
ATP synthesis, which leads to energy deficits and increases ROS generation. This 
loss in mitochondrial membrane potential, induced by Meth, also leads to the 
release of mitochondrial proteins such as cytochrome C and apoptosis inducing 
factor (AIF) into the cytosol. Likewise, it has been shown that cytochrome C is 
implicated in cytoskeleton rearrangements through proteolysis of cytoskeletal 
proteins in a caspase-3-dependent manner (Fig.4) (Krasnova and Cadet 2009). 
 
 
 
Figure 4. The role of caspase activation in the apoptotic pathway. Cellular stress promotes 
the expression of BH3 proteins, which binds Bax/Bak channels in the mitochondria, leading to the 
release of cytochrome c. Cytochrome c activates the apoptosome, which activates both caspases 3 
and 7 and triggers apoptosis. Adapted from (Adrain and Martin 2006).   
 
1.1.1.4 Excitotoxicity 
Excitotoxicity is mediated by exacerbated glutamate release and activation 
of ionotropic glutamate receptors, mainly the NMDA sub-type. It has already been 
shown that Meth induces an exacerbated release of glutamate causing 
neurotoxicity (Krasnova and Cadet 2009). Increased nitric oxide (NO) and reactive 
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nitrogen species (RNS) induced by Meth administration, inhibits oxidative 
phosphorylation, causing ATP depletion in neurons. Such effect is followed by a 
disruption in the sodium gradient across the neuronal plasma membrane and 
alters the membrane potential, resulting in further glutamate release and 
neuronal damage (Brown 2010). This increase in glutamate release induces 
hyperactivation of the NMDA receptors, increasing Ca
2+
 influx and activating 
several intracellular enzymes, such as Nitric Oxide Synthase (NOS). The calcium 
influx and the activation of NOS can lead to the establishment oxidative stress in 
neurons by the formation of ROS and RNS, further contributing for neuronal 
damage and neurodegeneration (Dawson, Beal et al. 1995, Lipton and Nicotera 
1998). 
1.1.1.5 Reactive species and hyperthermia 
 The production of ROS and RNS induced by Meth arises mainly from the 
disruption of dopaminergic system and excessive DA oxidation and the 
subsequently formation of toxic substances such as the radical superoxide 
(Yamamoto and Zhu 1998). ROS react with and oxidize many cellular constituents 
such as proteins, nucleic acids and lipids. While the brain is particularly 
vulnerable to the excess of such reactive species, oxidative stress can 
significantly disrupt neuronal signalling and synaptic homeostasis (Slemmer, 
Shacka et al. 2008). 
 Hyperthermia appears as an important factor in neurotoxic responses 
induced by Meth (Krasnova and Cadet 2009). Meth increases body temperature by 
enhancing heat production and retention. This psychostimulant increases 
metabolic activation and augment vasoconstriction directly contributing for 
hyperthermia induction (Matsumoto, Seminerio et al. 2014). Even though it is not 
clear how Meth induces hyperthermia, it seems that the disruption of the 
dopaminergic system is a critical event. Studies have demonstrated that the 
prevention of hyperthermia by low ambient temperature blocked the Meth-
induced increase in DA oxidation, preventing its toxic effects. Likewise, it has 
been shown that hyperthermia facilitates Meth-induced ROS production further 
potentiating the Meth toxic effects (Krasnova and Cadet 2009). 
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1.2 Neuroinflammation 
Neuroinflammation is a term used to designate immune responses at the 
level of central nervous system (CNS). This inflammatory response differs from 
peripheral inflammation mainly by the cells involved. In inflammatory responses 
of the brain parenchyma, the cells involved are mainly, microglia, astrocytes, 
neurons and circulating leukocytes. BBB that physically separates the CNS from 
others tissues can be stimulated and become more permeable, enabling the entry 
of leukocytes into the brain. TNF-α, IL-6, IL-1β and others pro-inflammatory 
cytokines modulate the permeability of BBB (Merrill and Murphy 1997). 
Exacerbation of neuroinflammatory responses can result in synaptic impairment, 
neuronal cell death and several neurodegenerative diseases (Lyman, Lloyd et al. 
2014). 
1.2.1 Microglia 
Nissl was the first to recognize microglial cells, characterizing them as 
reactive neuroglia and suggesting that such cells had the capacity of migrating 
and phagocyting (Nissl 1899). Many years later, in 1932, Pio del Rio-Hortega, for 
the first time, distinguished microglia from macroglia and suggested that the 
formers were of mesodermal origin. Hortega also proposed that microglia would 
enter the brain early during development and would be found dispersed 
throughout the CNS (del Río Hortega 1932). He additionally recognized that 
microglia experience cell shape transformation after a pathologic condition, 
acquiring an amoeboid morphology (Kettenmann, Hanisch et al. 2011). 
Nowadays, all of these statements are not only perfectly plausible but also 
well characterized. Microglia are a small and distinct population of glial cells that 
differs from macroglia in origin, function, morphology and gene expression 
profile. Glial cells represent more than 90% of the human brain, and 10% of the 
adult glial cell population in the normal brain is composed of microglia. These 
cells can support and protect neuronal cells, being distributed throughout the 
brain and the spinal cord parenchyma, although there are differences between 
their density in different CNS regions. The hippocampus, basal ganglia and 
substantia nigra are the most microglia-enriched areas of the CNS (Kim and de 
Vellis 2005, Walter and Neumann 2009, Greter and Merad 2013). 
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1.2.1.1 Origin of Microglia 
Unlike the other cells in the CNS, that are derived from the neuroectoderm, 
microglia are derived from the mesoderm. Before the BBB formation, microglial 
cells derive from embryonic hematopoietic precursors that colonize the CNS 
during early development. Primitive macrophages derived from the yolk sac 
migrate through the blood vessels to the neuroepithelium to originate microglia. 
After that, the BBB formation segregates the developing brain from fetal liver 
haematopoiesis, isolating the primitive macrophages poll, which segregates these 
populations. Microglial cells expand and colonize the whole CNS and maintain 
themselves until adulthood, proliferating during all development as well as in the 
challenged adult brain during inflammatory processes (Ling and Wong 1993, 
Ginhoux, Lim et al. 2013). 
However, this does not mean that in special cases, as inflammatory 
conditions, circulating monocytes or any other bone marrow-derived progenitors 
cannot migrate into the CNS, to support the resident microglia population (Fig.5). 
Nevertheless, it is not clear whether this foreign population persist to become 
permanently incorporated in the neuronal parenchyma, or are a momentary 
addiction to the endogenous pool. It also remains unknown if new microglia 
population are functionally and morphologically equivalent to the resident 
microglia (Saijo and Glass 2011, Ginhoux, Lim et al. 2013, Greter and Merad 
2013). 
Microglial cells display a plethora of phenotypic markers of the 
macrophage lineage and several of them are surface antigens/receptors with 
important functional roles. These small cells express the Csf-1 receptor (CD115), 
fraktalkine receptor (Cx3cr1), glycoproteins (F4/80; CD68), integrin (CD11b), Iba-
1 and low levels of CD45 (Greter and Merad 2013). 
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Figure 5. Primitive macrophages existing in the yolk sac migrate and colonize the 
neuroepithelium to give rise to microglia. These cells colonize the CNS by proliferating during brain 
development. However, in the inflamed brain, circulating monocytes can also enter the CNS for 
supplementing further the microglia population. Adapted from (Ginhoux, Lim et al. 2013).  
 
1.2.1.2 Steady-state microglia and homeostasis in the CNS 
Adequate microglia functioning is essential for the CNS homeostasis in 
health and disease. Non-appropriate microglia activation is observed in brain 
pathologies, contributing for disease progression and neuronal damage. 
Microglia are not only the first cell type that respond to a CNS challenge, such as 
infiltrating pathogens but also execute important roles in CNS homeostasis, such 
as regulation of synapse function, neurogenesis, production of trophic factors 
and clearance of apoptotic cells and debris (Cronk and Kipnis 2013). 
In normal conditions microglia are in the steady state, exhibiting an 
extensively branched morphology. In the surveillance state, these cells surround 
the healthy CNS parenchyma continuously extending and retracting their 
processes, effectively surveilling the CNS parenchyma (Boche, Perry et al. 2013). 
This surveillance state can be modulated by neuron-derived signals. The CX3C-
chemokine ligand 1, which is expressed by neurons, binds to CX3C receptor 
(CX3CR1) in microglia, playing an important role in inhibiting microglia-induced 
neurotoxicity. Also, in this branching phenotype, microglia secrete neurotrophic 
factors such as insulin-like growth factor 1 (IGF1), nerve growth factor (NGF), 
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transforming growth factor-β (TGF-β) and brain-derived neurotrophic factor (BDNF) 
that are important for neuronal function and synaptic activity. Still, the interaction 
between neuronal proteins such as CD47, CD200 and CD22 with their respective 
receptors in microglia (CD172, CD200R, CD45) has also been reported to block 
pro-inflammatory activation of microglia (Fig.6) (Hanisch 2002, Saijo and Glass 
2011, Chavarría and Cárdenas 2013, Suzumura 2013). However, this ramified 
microglia stage rapidly modifies when these cells detect some environmental 
change and, in response, microglia migrate to the area of this misbalance and 
rapidly change their morphology and function (Cronk and Kipnis 2013). 
 
 
 
Figure 6. Under normal conditions, microglia exhibit a branched morphology. This 
phenotype is maintained in part through interactions between neuronal signals and the 
correspondent microglia receptors. Adapted from (Saijo and Glass 2011). 
 
 1.2.1.3 Modulation of microglial cell phenotypes 
According to macrophages classification, microglia are classified into M1 
and M2 phenotypes. The M1 phenotype or classical activation is cytotoxic, with 
increased phagocytosis and release of pro-inflammatory cytokines, such as, IL-1β, 
TNF, IL-6 and IL-23 in addition to ROS and RNS. Interferon, lipopolysaccharide 
(LPS) and TNF stimulus are associated with triggering the M1 polarization, a 
response associated with host defence to pathogens. However, this classical 
activation may cause damage to others cells, inclusive neurons. 
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M2 polarization or alternative activation is characterized by a 
neuroprotective profile through the release of anti-inflammatory cytokines and 
growth factors. There are two types of M2 polarization, M2 wound healing and 
M2 regulatory. The M2 wound healing is stimulated by IL-4 and IL-13 and this 
function is related to tissue repair, phagocytosis and increased production/ 
remodelling of the extracellular matrix. In this phenotype, microglia produce 
extracellular matrix complements, arginase 1 and chitinase. On the other hand, 
the M2 regulatory phenotype is stimulated by IL-10, displays high phagocytic 
activity and inhibits inflammatory processes. This regulatory/alternative 
activation also includes the production of TGFβ1 and IL-10 (Raivich, Bohatschek et 
al. 1999, Saijo and Glass 2011, Boche, Perry et al. 2013). 
 
 
Figure 7. Microglial cells polarization: M1 and M2. Pro-inflammatory factors such as INFϒ 
and TNF induce microglial M1 phenotype and anti-inflammatory factors such IL-4, IL-5 and IL-10 
polarize microglia for M2 phenotype. NOX2:; INFϒ: Interferon-ϒ; TNF: Tumor necrosis factor; IL-
4:Interleukin 4; IL-5:Interleukin 5;  IL-10:Interleukin 10;  IL-13:Interleukin 13.  Adapted from (Rojo, 
McBean et al. 2014). 
 
1.2.1.3.1 Classical microglia activation 
Activated microglia are identified by an “amoeboid” morphology in 
response of process retraction, becoming highly motile, migrating to the 
misbalanced area, proliferating and phagocyting cell debris and/or damaged 
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neurons. Once activated, microglia secrete a variety of factors such as 
inflammatory cytokines, ROS and RNS, in addition to an enhance in the 
expression of MHCII, which is required for activation of naïve T lymphocytes 
(Fig.8) (Hanisch 2002, Saijo and Glass 2011).  
 Microglia cells express pattern recognition receptors (PRRs) that identify 
pathogen-associated molecular patterns (PAMPs). The recognition of PAMPs by 
microglia through PRRs normally induces the classical microglial activation (Saijo 
and Glass 2011). 
 
 
 
Figure 8. Classical activation microglial cells triggered by PAMPs participate in both innate 
and adaptive responses. Microglia express pattern recognition receptors (PRRs) that identify various 
pathogen-associated molecular patterns (PAMPS). Follow ing the recognition of PAMPs microglia 
induces the production of cathelicidin-related antimicrobial peptide (CRAMP), TNF, IL-18, CCL2, ROS 
and NO.  Activated microglia also express MHC class II molecules to enable them to present 
antigens to T cells.  In addition, activated microglia produce IL-12, IL-23 and TGF β that activates T 
cells. CCL2: CC-chemokine ligand 2; ROS: reactive oxygen species; NO: nit ric oxide; TCR:  T cell 
receptor; TNF: tumour necrosis factor; IL-18: Interleukin 18; IL-23: Interleukin 23; IL-12: Interleukin 
12; TGF β: Transforming growth factor β; MHC class II: Major histocompatibility class II. Adapted 
from (Saijo and Glass 2011). 
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1.2.1.3.2 Alternative microglial activation 
Alternative microglial activation is associated with damage resolution, such 
as tissue repair and extracellular matrix reconstitution. This microglial activation 
is induced by anti-inflammatory cytokines such as IL-4, IL-13 and IL-10. Once 
activated, microglial cells produce IL-10, IL-4, IGF-1 and TGF-β, which contribute 
for inflammatory resolution. This phenotype is characterized by the modification 
of inflammatory signals, promoting debris clearance and neuroprotective 
proprieties (Fig.9) (Saijo and Glass 2011, Zhou, Spittau et al. 2012, Wang, Zhang 
et al. 2013). 
Figure 9. Alternative microglial activation induced by IL-4 and IL-13. This activation induces 
production of IL-4, IL-10, TGF-β and IGF-1. IL-4: interleukin 4; IL-13: interleukin 13; IL-10: interleukin 
10; TGF- β: transforming growth factor 1 and IGF-1: insulin-like growth factor 1. Adapted from 
(http://jonlieffmd.com/blog/are-microglia-the-most-intelligent-brain-cells). 
 
1.2.1.4 Microglial migration and proliferation 
In a trauma response, microglia become amoeboid (round and 
disbranched) and migrate to the injury site. Damage in the CNS leads to a release 
of chemotactic factors such as CXCL10, which induces microglial migration. 
Studies have  demonstrated in vivo and in vitro that microglia migrate along 
chemotactic gradients including morphine, epidermal growth factor, 
cannabinoids and bradykinin (Walter, Franklin et al. 2003, Garden and Möller 
2006, Noda and Suzumura 2012, Shi, Yuan et al. 2013). Extracellular ATP and 
ADP release from traumatic brain also stimulate microglia migration. Besides, 
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NOS play an important role in microglial migration.  A significant reduction in 
microglial accumulation was observed in lesion sites with decreased NOS 
production (Chen, Kumar et al. 2000, Garden and Möller 2006). 
Microglia proliferation is essential for an adequate immune response. 
Cytokines such as IL-1β, IL-4 and INFϒ have been described as proliferation 
inducers; however, the most potent factor that induces microglia proliferation is 
GM-CSF. Neurotrophic factors, such as BDNF and NT-3, released by activated 
microglia, also induce the proliferation of these cells (Garden and Möller 2006). 
 
1.2.1.5 Microglia phagocytosis 
Microglia are the predominant phagocytes in the CNS. Phagocytosis is the 
processes that comprehend recognition, internalization and digestion of the 
antigen by a phagocytic cell (Lampron, Pimentel‐Coelho et al. 2013). Recognition 
mechanisms can be mediated by cellular receptors of the pathogen by antibodies 
or complement proteins, which are recognized by specific receptors in the 
phagocyting cell. 
There are two distinct functional types of phagocytic receptors in 
microglia: (1) receptors that recognise pathogens and simultaneously stimulate 
pro-inflammatory responses, for example, in the case of Toll-like receptors (TLRs) 
or Fc- receptors’ which interaction with antigens, and (2) receptors that identify 
apoptotic material and stimulate an anti-inflammatory response, such as 
phosphatidylserine (PSRs) or receptor expressed on myeloid cells-2 (TREM-2) 
(Fig.8). The removal of apoptotic cells by phagocytosis is defined as a silent 
process, which is essential during brain development, for example (Neumann, 
Kotter et al. 2009). 
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Figure 10. Microglia phagocytic response. In inflammatory response microglia detect the 
pathogen, which induces the phagocytic response and leads to the release pro-inflammatory 
mediators by microglia. Without inflammation microglial cells detect apoptotic cells, phagocyte and 
release anti-inflammatory signals. Phagocytic receptors: purine receptors (PRs); phosphatidylserine 
receptors (PSRs); complement receptors (CRs); toll like receptors (TLRs); Fc-receptors (FcR); 
scavenger receptors (SRs) and triggering receptor expressed on myeloid cells-2 (TREM2). Adapted 
from (Neumann, Kotter et al. 2009). 
1.2.2 Astrocytes 
Astrocytes are the major and most abundant glial cell type in the CNS 
(Mahesh, Dhandapani et al. 2006). These specialized cells outnumber neurons by 
over five-fold and are ubiquitous throughout all CNS regions (Hamby and 
Sofroniew 2010). Astrocytes, as the name suggests, are star-shaped cells 
distributed throughout the brain and the spinal cord (Montgomery 1994). These 
glial cells are derived from the neuroectoderm during embryonic development 
and are essential for brain homeostasis in health and disease (Farina, Aloisi et al. 
2007). Traditionally, these cells are divided into two main subtypes, protoplasmic 
and fibrous based on their morphologic appearance and anatomical localization 
in the CNS (Montgomery 1994). Protoplasmic astrocytes are found in the grey 
matter and exhibit many branching processes.  On the other hand, fibrous 
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astrocytes are most common in the white matter bearing many long processes, 
which intersect blood capillaries through their end-feet (Gee and Keller 2005). 
Functionally, protoplasmic astrocytes are associated with neuronal cell bodies and 
synapses while fibrous astrocytes are associated with axons (Allen and Barres 
2009, Chaboub and Deneen 2012). 
Astrocytes play important physiologic roles in the brain, including the 
regulation of blood flow, which supplies neurons with energy and other 
metabolites, participation in synaptic dynamics, maintenance of extracellular 
ionic homeostasis and recycling of neurotransmitters (Figure.11) (Allen and 
Barres 2009, Hamby and Sofroniew 2010).  
 
Figure 11. Representation of the main roles of astrocytes in brain homeostasis. Astrocytic 
excitatory amino acid transporters (EAATs) are responsible for the uptake of a large fraction of 
glutamate (Glu) at the synapse. Glu is converted into glutamine (Gln) by glutamine synthetase (GS) 
and shuttled back to neurons for glutamate resynthesis. Glutamate uptake by astrocytes is 
accompanied by Na
+
 entry which is counteracted by the action of the Na
+
/K
+
 ATPase. The resulting 
increase in ADP/ATP ratio triggers anaerobic glucose utilization in astrocytes and glucose uptake 
from the circulation through the glucose transporter GLUT1. The lactate (Lac) produced is shuttled 
to neurons through monocarboxylate transporters MCTs, where it can be used as an energy 
substrate after its conversion to pyruvate (Pyr). Abundant carbonic anhydrase (CA) in astrocytes 
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converts CO
2
 into H
+
 and HCO
3
 
-
. Two HCO
3
 
-
 are transported into the extracellular space along 
vyith one Na
+
 via the Na
+
-HCO
3
 
–
 co-transporter (NBC), thereby increasing the extracellular buffering 
power. Protons left in the glial compartment may drive the transport of lactate outside of astrocytes 
and into neurons through MCTs. Excess H
+
 in neurons is extruded via sodium-hydrogen exchange 
(NHE). Astrocytes buffer excess potassium ions (K
+
) released into the extracellular space as a result 
of neuronal activity. K
+
 travel through the astrocytic syncitium down their concentration gradient 
and are released in sites of lower concentration. Astrocytes release glutathione (GSH) in the 
extracellular space where it is c leaved by the astrocytic ectoenzyme γ-glutamyl transpeptidase (γGT). 
The resulting CysGly selves as a precursor for neuronal GSH synthesis. X represents an acceptor for 
the γ-glutamyl moiety in the reaction catalyzed by γGT.  Adapted from (Bélanger and Magistretti 
2009). 
 
Recent evidence also implicates astrocytes as important immune regulators 
in the CNS. Their strategic location in close association with other glial cells, 
neurons and blood vessels allows them to efficiently respond to changes in the 
CNS environment (Fig.12).  
 
 
Figure 12. The strategic location of astrocytes, close microglia, neurons and blood vessels, 
make these cells play an important role in both innate and adaptive immunity. Adapted from (Allen 
and Barres 2009) 
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Astrocytes also respond to many forms of CNS injury, such as infection, 
trauma and ischemia. Similarly to microglia, astrocytes may become reactive, a 
process known as astrogliosis, which is characterized by changes in gene 
expression profile, proliferation, and migration. In this activated stage, astrocytes 
release a plethora of inflammatory mediators such as cytokines, chemokines and 
growth factors (Ridet, Privat et al. 1997, Sofroniew 2009). 
 These inflammatory mediators produced by astrocytes, participate in tissue 
repair and remodelling both in the brain and spinal cord following an acute injury 
to the neuronal parenchyma. These cells also modulate neuronal viability by 
restricting the spread of inflammatory cells and infection. However, reactive 
astrocytes can also be harmful to neurons by producing and releasing neurotoxic 
amounts of glutamate and ROS and by further exacerbating neuroinflammation 
via the increased release of pro-inflammatory cytokines (Sofroniew and Vinters 
2010). 
Astrocytes express major histocompatibility complex class II (MHC II) 
molecules indicating their functional capability as antigen presenting cells, 
contributing for adaptative immunity (Dong and Benveniste 2001). Astrocytes 
also display direct effects on endothelial cells, for example, regulating the 
permeability of the BBB, which indirectly contributes for the recruitment of T 
lymphocytes to the brain (Bush, Puvanachandra et al. 1999, Argaw, Zhang et al. 
2006, Argaw, Gurfein et al. 2009). Once within the brain, these T cells may affect 
the immune response and modulate brain homeostasis by the secretion of a 
variety of both pro and anti-inflammatory cytokines (Dong and Benveniste 2001). 
Therefore, immune activation of astrocytes can either be beneficial or harmful 
depending on the conditions under which activation occurs. 
 
1.2.2.1 Interplay between Microglia and Astrocytes 
Astrocytes produce and secrete immune mediators such as INF-ϒ, TNF, IL-
1β and IL-6, which may lead to pro-inflammatory microglia activation. On the 
other hand, the release of TGF-β and IL-10 may shift microglia activation toward 
an anti-inflammatory signature (Hanisch 2002, Lu, Ma et al. 2010, Norden, Fenn 
et al. 2014). Chemokines such as CCL2 and CXCL10 also modulate microglia 
functions such as migration (Flynn, Maru et al. 2003, Farina, Aloisi et al. 2007). 
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Studies have demonstrated that fractalkine (CX3CL1) expressed by astrocytes 
leads to inhibition of neurotoxicity  by suppressing the production of pro-
inflammatory cytokines and NO by activated microglia (Mizuno, Kawanokuchi et 
al. 2003). Several studies have also demonstrated that microglia treated with 
astrocyte conditioned medium, reduce iNOS expression and ROS production 
induced by H
2
O
2 
and INF-ϒ through an increased expression of microglial 
antioxidant enzymes (Min, Yang et al. 2006, Shih, Fernandes et al. 2006). 
 
1.3 Neuroinflammation and Methamphetamine 
 Microglia have recently been implicated as mediator of Meth-induced 
neurotoxicity. Some studies have shown that Meth consumption might cause both 
microglial and astrocytes activation. Regarding microglia activation, it has already 
been shown that Meth induces a substantial microglial response in areas of the 
brain showing neuronal degeneration (Krasnova and Cadet 2009). 
 It was also demonstrated that Meth promotes neuroinflammation by 
damaging the dopaminergic system, inducing hyperthermia, increasing ROS 
generation and glutamate release. Furthermore, this psychostimulant also 
increases the release of pro-inflammatory cytokines by microglia (Gonçalves, 
Martins et al. 2008, Tocharus, Khonthun et al. 2010). All of these elements are 
recognized either to cause or aggravate neuronal damage, and some studies have 
suggested that microglial cell activation seems to precede the appearance of 
damage produced by Meth consumption (LaVoie, Card et al. 2004). This has been 
confirmed by studies demonstrating that anti-inflammatory drugs protect against 
Meth-induced neurotoxicity (Asanuma, Tsuji et al. 2003, Tsuji, Asanuma et al. 
2009). 
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Figure 11. Signalling pathways of Meth-induced neurodegeneration and loss of 
dopaminergic terminals. Adapted from (Cadet, Krasnova et al. 2007).  
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2 Aim 
Our main goal was to comprehend how isolated microglia (assessed using 
primary cultures) would respond to Meth exposure. For that we will analyse pro -
inflammatory and anti-inflammatory markers in cortical purified microglial cells 
exposed to Meth. We will also study activation markers in cultured cortical 
astrocytes challenged with Meth. Finally, we will observe the effect of conditioned 
media from Meth-treated astrocytes on cultured microglial cells analysing 
different set of classical activation markers.  
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3 Experimental Procedures 
3.1 Reagents 
 DMEM/F-12 GlutaMAX™-I, DMEM GlutaMAX™-I, Fetal Bovine Serum (FBS), 
Penicillin-Streptomycin (10.000U/ml) 0.25% trypsin-EDTA, HBSS and CellROX® 
were acquired from Life Technologies. Granulocyte macrophage colony-stimulant 
factor (GM-CSF) was obtained from Peprotech®, latex beads and poly-D-lysine 
were obtained from Sigma-Aldrich. 
3.2 Mixed glial cell cultures 
Primary mixed glial cell cultures were obtained from cerebral cortices of 
newborn Wistar rats (P1-P3). The cortices were separated from other tissues; the 
meninges were removed in HBSS and then dissociated with 0.25% trypsin-EDTA. 
Glial cells were plated into T75 flasks coated with poly-D-lysine in DMEM/F-12 
GlutaMAX™-I supplemented with 10% FBS and 1% penicillin/streptomycin. These 
cells were cultured for 10 days at 37ºC in a humidified incubator in an 
atmosphere containing 5% CO
2
 and 95% O
2 
ratio. The culture media was totally 
replenished twice a week. Each mixed glial cell culture batch was shaked three 
times, once a week, for collecting microglial cells (3.2.1) and, after that, it was 
used for purified astrocyte cultures (3.2.2). 
3.2.1 Purified microglial cell cultures 
Mixed glial cell cultures, 10 days after plating, were submitted to orbital 
shaking three times, once a week, at 200 rpm for 2 hours to detach microglia 
cells. After that, culture medium containing the microglial cells in suspension was 
centrifuged at 290g for 10min. The pellet was re-suspended in DMEM/F-12 
GlutaMAX™-I supplemented with 10% FBS, 1% penicillin/streptomycin and 1ng/ml 
granulocyte macrophages colony-stimulating factor (GM-CSF). Microglial cells 
were plated in non-coated coverslips on the bottom of a 12-well tissue culture 
plate (1×10
5 
cells/ml) or in non-coated culture dishes (2x10
5 
cells/ml), and the 
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media was totally replenished on the day after plating. The cells were cultured for 
3 to 4 days at 37ºC in a humidified incubator in an atmosphere containing 5% CO
2
 
and 95% O
2 
ratio. 
3.2.2 Purified astrocyte cell cultures 
 After the third shake of the mixed glial cell culture, the adherent cells were 
washed with PBS (phosphate buffer saline solution), trypsinized (0.25% trypsin-
EDTA), and splited to non-coated 100mm culture dishes. Splited cultures were re-
splited, at least, three more times, in order to obtain purified astrocyte cultures. 
These cultures were then frozen (10% DMSO; 20% FBS in DMEM GlutaMAX™-I) until 
use. For experimental procedures, these cells were thaw and plated. 
3.3 Drug treatment 
The drug used was (+)- Methamphetamine hydrochloride obtained from 
Sigma under an INFARMED license. In order to be used for cell treatment, the 
compound was dissolved in sterile PBS and incubated in microglial or astrocyte 
cell culture media. Microglial cells and astrocyte were exposed to 10 or 100 μM of 
Meth for 24 hours.  
The concentrations of Meth used were based on previous in vitro studies 
published (Lee, Hennig et al. 2001) and (Narita, Miyatake et al. 2006). These 
concentrations are similar to levels found in blood, urine or tissue samples of 
Meth users that range from ≤ 2 μM to 600 μM (Takayasu, Ohshima et al. 1995, 
Kalasinsky, Bosy et al. 2001, Schepers, Oyler et al. 2003). 
3.4 Phagocytic assay  
Primary cultures of microglial cells were incubated with fluorescent latex 
beads with 0.5 μm diameter in order to analyse the changes in phagocytosis 
capacity induced by Meth. Latex beads (green) were diluted in the culture medium 
(1:1000 (v/v)) and incubated 24 hours after Meth treatment for 1 hour at 37ºC. 
After beads incubation, cells were washed three times with PBS and fixed for 12 
minutes in 4% MP-PFA (Paraformaldehyde microtubule protection buffer)  : 65mM 
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pipes, 25mM HEPES, 10mM EGTA, 3mM MgCl
2
, pH 6.9).  The number of beads per 
cell was counted and the phagocytic efficiency was calculated based on a 
weighted arithmetic mean of phagocyted beads per cell (Liu, Hao et al. 2006). In 
order to establish a score, beads per cell were classified according to the number 
of phagocyted beads as described in the following table: 
 
Range of phagocyted Beads Score 
1 to 7 1 
8 to 14 2 
15 to 21 3 
22 to 28 4 
28 to 35 5 
Up to 36 beads 6 
 
Table 1. Score of beads per cells. 
 
The number of cells classified in each score was multiplied by the 
respective score number, as a weight value for the weighted arithmetic mean, as 
described by the following equation: 
 
?̅? =
(𝑛º 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑠𝑐𝑜𝑟𝑒 1 × 1) + (𝑛º 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑠𝑐𝑜𝑟𝑒 2 × 2) + ⋯ + (𝑛º 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑠𝑐𝑜𝑟𝑒 6 × 6)
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
 
 
3.5 Oxidative Stress assay 
Primary microglial cultures were incubated with CellROX® Oxidative Stress 
Reagents in order to analyse the production of ROS induced by Meth. CellROX® 
Green Reagent was added to primary cultures 24 hours after drug treatment at a 
final concentration of 5 μM, for 30 min at 37ºC. Then, cells were washed three 
times with PBS and fixed for 12 minutes in 4% MP-PFA. 
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3.6 Astrocyte-conditioned medium assay 
 Astrocytes were thaw and plated. After 2 days, cells were treated for 24 
hours with different Meth concentrations (10 μM and 100 μM). Afterwards, the 
medium was collected and stored at -80ºC until use. The conditioned medium 
was added to microglial cell cultures and, 24 hours later, cells were washed three 
times with PBS and fixed for 12 minutes in 4% MP-PFA. Control microglia 
conditions received astrocyte conditioned medium from non Meth exposed 
cultures. 
3.7 Immunocytochemistry 
After MP-PFA fixation, cultures were permeabilized with 0.5% Triton X-100 
in PBS for 10 min at room temperature (RT), washed with PBS three times for 10 
minutes and then the coverslips were blocked with 3% bovine serum albumin 
(BSA) in PBS for 60 min at RT. Afterwards, cells were incubated with primary 
antibody (Table 2) or Alexa conjugated 647 Phalloidin (1:50) overnight at RT in 
blocking solution. Cells were then washed three times for 10 min and incubated 
with a secondary antibody Alexa Fluor® 488, 568 or 647 in blocking solution for 
one hour at RT. Finally, cells were incubate with DAPI, a nuclear staining, for 15 
minutes, and washed in PBS for 10 minutes with PBS. Coverslips were mounted 
using Immu-Mount™ mounting media and observed using DIM6000B inverted 
microscope (Leica Microsystem) with an HCX Plan Apo 63x/1.4-0.6 NA oil 
immersion objective. 
 
 
Primary antibody Dilution Reference Company 
Anti-Arginase 1 1:100 Sc-18354 Santa Cruz Biotechnology 
Anti-CD11b 1:200 Ab8879 Abcam 
Anti-GFAP 1:500 G9269 Sigma-Aldrich 
Anti-iba-1 1:500 016-20001 Wako 
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Anti-NOS2 1:200 Sc-650 Santa Cruz Biotechnology 
 
Table 2. List of primary antibodies used in immunocytochemistry analysis. 
3.8 Intensity Quantification 
 For the intensity quantification, images were exported using the Leica LAS 
AF program in TIF format (16-bit). In ImageJ software these micrographs had their 
background subtracted using 50%-off pixels radius by the rollerball algorithm. 
Next, cells were segmented using the OTSU algorithm with automatic 
complementation for both the bottom and upper threshold ramps with 
background values set to black and foreground values set to red. Individual 
segmented cells were transposed to ImageJ’s ROI manager using the analyse 
particles tool. A range between 100-to-infinity of non-calibrated pixels2 defined 
each segmented cell. Mean gray values for the intensities were returned for each 
cell individually using the multi-measure function on ImageJ`s ROI manager. 
3.9 Morphologic assessment of microglia  
Images were processed in ImageJ software to assess microglial cell 
morphology. Microglia were immunostained for CD11b and images were acquired 
in a DIM6000B inverted microscope (Leica Microsystem). Micrographs were 
exported as 16 bit tiff images, segmented, converted to binary 8 bit gray scale 
and the background subtracted 25% by the rollerball algorithm in ImageJ.  FracLac 
plugin was implemented to assess the complexity of microglia morphology on a 
cell-by-cell basis. Regions of interest were traced using the particle analyzer tool 
in ImageJ to contour microglial cells and complexity (D
B
) was extracted by box 
counting with FracLac plugin as previously described (Karperien, Ahammer et al. 
2013). 
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3.10 Quantitative Real-Time RT-PCR 
3.10.1 RNA isolation from microglial and Astrocyte cells. 
 The total mRNA was isolated using RNeasy Mini Kit (Qiagen) according to 
manufacturer’s instructions. Briefly, samples were lysed in a denaturating buffer 
and homogenized. Ethanol was added into the lysate to provide ideal binding 
conditions. The lysate was loaded onto RNeasy Mini spin column and, after 
washes, concentrated RNA was eluted in 20µl RNase free water as schematically 
explained in Fig 12. The total amount of RNA yields was measured using 
NanoDrop® 1000 Spectrophotometer (Thermo scientific) at 260nm and the purity 
of the RNA was evaluated through the ratio 260/280nm. 
 
Figure 12. Procedure of RNA extraction by RNeasy Mini kit (Qiagen). Adapted from 
(http://www.qiagen.com/pt/resources/resourcedetail?id=14e7cf6e-521a-4cf7-8cbc-bf9f6fa33e24&l 
ang=en). 
3.10.2 Reverse transcription for cDNA synthesis 
cDNA was synthesized using 1μg of total RNA of samples through RT2 Easy 
First Strand (Qiagen) according to manufacturer’s instructions. Briefly, to 1μg of 
RNA was added buffer GE for each sample in order to eliminate genomic DNA and 
then, the reverse transcriptase mix was added, reaching a final volume of 20μl. 
On a thermocycler the samples were heated until 42°C for 15 min and then 
heated until 95°C for 5 minutes, finishing the reaction. These samples were 
stored at -20°C until used. 
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3.10.3 Quantitative Real-time PCR and Analysis 
 Gene expression of classical inflammatory markers was evaluated using 
quantitative real time PCR (qRT-PCR). The PCR was performed using iQ™5 
multicolor real time PCR detection system (Bio Rad). The reaction was performed 
following the iQ™ SYBR® Green Supermix manufacturer’s protocol.  The reaction 
components are summarized in table 3. 
Component Volume per 
20uL reaction 
iQ™ SYBR® Green Supermix 
(2×) 
10μl 
Primers Forward Variable 
Primer reverse Variable 
cDNA diluted (1:10) 2μl 
H
2
O Variable 
Total 20μl 
 
Table 3. Real Time PCR reaction components. 
 
 
 For TNF, iNOS, IL-10 and TGF-β detection, the primers concentration used 
was 200nM, for YWHAZ (reference gene) 250nM and for IL-1β and IL-6 300nM. 
The primers (all obtained for Sigma-Aldrich) used in PCR reactions were described 
in table 4. 
 
Primers Sequences (5’      3’) 
Forward Reverse 
IL-10 ATCCGGGGTGACAATAACTG TGTCCAGCTGGTCCTTCTTT 
IL-1β TAAGCCAACAAGTGGTATTC AGGTATAGATTCTTCCCCTTG 
IL-6 ACTCATCTTGAAAGCACTTG GTCCACAAACTGATATGCTTAG 
29 
iNOS AGCCGTAACAAAGGAAATAG ATGCTGGAACATTTCTGATG 
TGF-β TGAGTGGCTGTCTTTTGACG GTTTGGGACTGATCCCATTG 
TNF-α CTCACACTCAGATCATCTTC GAGAACCTGGGAGTAGATAAG 
Ywhaz GATGAAGCCATTGCTGAACTTG GTCTCCTTGGGTATCCGATGTC 
Table 4 . List of primers used in qPCR. 
 
Each reaction was performed in duplicated and the PCR cycling profile for 
IL-1β, IL-6, iNOS, TNF-α and Ywhaz was 3 min at 94ºC for polymerase activation 
and DNA denaturation, followed by 40 cycles of 15 sec at 94ºC (denaturation), 20 
sec at 58ºC (annealing), and 15 sec at 72ºC (extension) and 81 cycles of 30 sec 
between 55ºC and 95ºC (final extension period). For IL-10 and TGF-β the cycling 
profile was 3 min at 94ºC for polymerase activation, followed by 40 cycles of 15 
sec at 94ºC (denaturation), 20 sec at 62ºC (annealing) and 81 cycles of 30 sec 
between 55ºC and 95ºC (final extension period). 
 Melting point analyses were performed for each reaction to confirm single 
amplified products. Gene expression was extrapolated from standard curves 
generated concurrently for each gene using a control cDNA dilution series. 
Results were analysed using iQ™5 Optical System software version 2.1(BioRad). 
All values were normalized to levels of the reference gene, Ywhaz, and expressed 
compared to unstimulated control samples. Results were calculated using relative 
quantification method, Pffalf (Pfaffl 2001) by following formula: 
 
3.11 Statistical analyses 
Data are shown as mean ± SEM (standard error of the mean). Statistical 
analysis of data was performed either using one-way ANOVA followed by 
Dunnett’s post-test or two-sample equal variance Student’s t test. Differences 
were considered significant for *p<0.05. Every experimental condition was tested, 
at least, in three sets of separate and independent experiments. Statistical 
analysis was performed using the GraphPad Prism® software version 6.02.  
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4 Results 
4.1 Methamphetamine does not induce a pro-inflammatory 
signature in microglial cells 
It was previously described that microglia activation represents an early 
step in Meth-induced neurotoxicity (Thomas, Dowgiert et al. 2004). In this 
section, primary cultures of microglial cells were used as a model to better 
understand the role of this cell type on Meth-induced neuroinflammation. For 
that, microglial cells were challenged with Meth 10 μM or 100 μM for 24 hours 
and, in order to examine the activation state of microglial cells, classical 
activation markers were observed such as cell morphology, phagocytosis 
efficiency, ROS production, iNOS expression and pro-inflammatory cytokines 
profile. 
 
Firstly, we analysed microglial cell morphology using a microglial marker, 
CD11b, and observed that cell complexity significantly increased when cells were 
incubated with Meth 100 μM (Fig.12), suggesting that Meth doesn’t induce an 
amoeboid morphology. We also evaluated the phagocytic capacity of microglial 
cells using inert fluorescent microbeads. For that, microglia were treated with 
Meth 10 μM or 100 μM and, as shown in Fig.13, the number of cells containing 
beads, the number of beads per cell and the phagocytic activity of microglial cells 
significantly decreased when these cells were treated with Meth 100 μM but not in 
cells treated with Meth 10 μM when compared to cells not treated with Meth. We 
concluded that Meth reduces the phagocytosis of microglial cells. 
Regarding ROS production, we observed that Meth at neither 10 μM nor 
100 μM was capable of increasing ROS production, as can be observed in figure 
14. Moreover, we also analysed iNOS expression and observed that Meth could 
not induce changes in iNOS expression when compared with untreated microglial 
cells (Fig.15). Pro-inflammatory cytokines and iNOS mRNA expression levels were 
also evaluated by qRT-PCR. Our results suggest that Meth did not induce any 
significant change in the mRNA levels of IL-1β, IL-6 or TNF. Microglial cells were 
incubated with both Meth 10 μM and 100μM in two different time points (3 and 
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24 hours; Fig 16 A-C). Regarding the mRNA expression of iNOS, it could not be 
detected any significant change at 24 hours of Meth exposure (Fig 16 D).  
The results described herein indicate that Meth does not induce a pro-
inflammatory activation of microglial cells. In order to better understand the Meth 
effect in primary microglial cultures, we hypothesized whether Meth could trigger 
an anti-inflammatory signature in primary microglial cell cultures. To answer this 
question we analysed anti-inflammatory hallmarks of microglia activation. 
Figure 12.  Meth increased the complexity in primary cortical microglial cells.  (A) 
Representative photomicrographs of purified microglial cells cultures treated w ith 10 μM or 100 μM 
of Meth for 24 hours stained for CD11b (red) and Dapi (blue). (B) Quantification of complexity show 
a significant increase of complexity on cells treated w ith Meth 100 μM compared w ith untreated 
cells (control). Results are expressed as mean ± SEM of three independent experiments. Statistical 
significant differences are signed as **p< 0.01 compared w ith control. Calibration bar: 10 μm  
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Figure 13. Meth reduced the phagocytosis in primary cortical microglial cells. (A) 
Representative photomicrographs of purified microglial cells cultures treated w ith 10 μM or 100 μM 
of Meth for 24 hours stained for CD11b (red) and Dapi (blue). (B-D) Quantification of phagocytosis 
activity show a significant decrease of phagocytosis on cells treated w ith Meth 100 μM compared 
w ith untreated cells (control). The graphs represent: percentage of cells w ith beads (B), number of 
beads per cell (C) and phagocytic efficiency (D). Results are expressed as mean ± SEM of three 
independent experiments. Values displayed were normalized in relation to the control group. 
Statistical significant differences are signed as *p< 0.05, **p< 0.01 compared w ith control. 
Calibration bar: 10 μm.  
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Figure 14. Effects of Meth in reactive oxygen species production by primary cortical 
microglial cells. (A) Representative photomicrographs of purified microglial cells cultures treated 
w ith 10 μM or 100 μM of Meth for 24 hours. (B ) Quantification of CellRox® (green) shows no 
significant changes when compared to control. Results are expressed as mean ± SEM of three 
independent experiments. Values displayed were normalized in relation to the control group. 
Calibration bar: 10 μm. 
Figure 15. Effects of Meth in nit ric oxide production by primary cortical microglial 
cells. (A) Representative photomicrographs of purified microglial cells cultures treated w ith 10 μM 
or 100 μM of Meth for 24 hours stained for iNOS (red) and Dapi (blue). (B) Quantification of 
inducible nit ric oxide synthase show not significant changes when compared to control. Results are 
expressed as mean ± SEM of three independent experiments. Values displayed were normalized in 
relation to the control group. Calibration bar: 10 μm  
34 
 
 
 
 
  
35 
 
Figure 16. Levels of classical pro-inflammatory markers mRNA in primary microglial 
cell cultures after Meth exposure.  The mRNA levels of (A) IL-1β, (B) IL-6, (C) TNF-α and (D) iNOS 
were analysed 3and 24 hours after Meth treatment, by RT-PCR. Results are expressed as mean ± 
SEM of three independent experiments. Values displayed were normalized in relation to the control 
group. 
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4.2 Methamphetamine does not trigger an anti-inflammatory profile 
in microglial cells 
 In order to evaluate whether Meth induces an anti-inflammatory signature 
in microglial cells we first evaluated Arginase 1 expression as an anti-
inflammatory marker. We found that Meth did not induce any significant changes 
in the expression of this anti-inflammatory marker for both doses (Fig. 17). Then, 
we evaluated the mRNA expression levels of anti-inflammatory markers by qRT-
PCR. Our results demonstrate that Meth induced no significative change in IL-10 
or TGF-β mRNA expression levels. The cells were tested for both Meth doses (10 
μM and 100μM) and, at two different time points (3 and 24 hours) after Meth 
exposure (Fig. 18). Taken together, these data suggest that Meth does not trigger 
an anti-inflammatory profile in cultured microglial cells. 
It was previously reported that Meth may induce microglial cell activation 
in vivo (LaVoie, Card et al. 2004, Thomas, Dowgiert et al. 2004, Sekine, Ouchi et 
al. 2008). In order to better comprehend how Meth could induce this pro-
inflammatory activation we hypothesized that other CNS cell type could 
contribute for his Meth-induced microglia activation in vivo. Likewise, we 
searched for cell types that could be influenced by Meth and found that Meth also 
regulates astrocytes reactivity in both in vivo and in vitro paradigms (Narita, 
Miyatake et al. 2005, Friend and Keefe 2013). Based on these facts, we 
hypothesized that Meth might modify astrocytes basal activation state, which 
could promote the release of pro-inflammatory mediators to indirectly influence 
microglial cell function. 
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Figure 17.  Effects of Meth on Arginase 1 expression, in primary cortical microglial 
cells. (A) Representative photomicrographs of purified microglial cells cultures treated w ith 10 μM 
or 100 μM of Meth for 24 hours. (B) Quantification of Arginase 1 (red) intensity shows no 
statistically significant changes compared to untreated cells (control). Results are expressed as 
mean ± SEM of three independent experiments. Values displayed were normalized in relation to the 
control group. Calibration bar: 10 μm.  
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Figure 18. Levels of (A) IL-10 and (B) TGF-β mRNA in primary microglial cell cultures 
after Meth exposure.  The mRNA levels were analysed 3and 24 hours after Meth treatment, by RT-
PCR. Results are expressed as mean ± SEM of three independent experiments. Values displayed 
were normalized in relation to the control group.  
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4.3 Methamphetamine does not regulate astrocytes reactivity 
In order to analyse Meth effects on astrocytes, we analysed astrocyte 
reactivity markers such as the expression of iNOS and GFAP, as well as the 
formation of actin stress fibers. As can be observed in figure 19, we found that 
Meth did not induce a significant change in the expression of iNOS in astrocytes 
24 hours after treatment. Then, we evaluated the Meth effect on the formation of 
actin stress fibers. For that we stained astrocytes F-actin with Phalloidin-
conjugated fluorochrome and observed that Meth could not increase stress fibers 
formation (Fig. 20). We also evaluated GFAP expression as a marker for in vitro 
astrogliosis. Surprisingly, we observed that Meth treatment significantly 
decreased GFAP expression in astrocytes primary cultures (Fig.21). 
Our results strongly suggest that, in presence of Meth, astrocytes do not 
become activated. Notwithstanding, we evaluated the effects of conditioned 
media (CM) of astrocytes treated with Meth in microglial cells. 
  
40 
Figure 19. Effects of Meth on iNOS expression, in primary cortical ast rocytes cultures. 
(A) Representative photomicrographs of purified astrocytes cells cultures treated w ith 10 μM or 100 
μM of Meth for 24 hours. (B) Quantification of iNOS (red) intensity shows no statistically significant 
changes compared to untreated cells (control). Results are expressed as mean ± SEM of three 
independent experiments. Values displayed were normalized in relation to the control group. 
Calibration bar: 10 μm. 
 
 
Figure 20. Effects of Meth, on st ress fibers formation, in primary cortical astrocytes 
cultures. (A) Representative photomicrographs of purified astrocytes cells cultures treated w ith 10 
μM or 100 μM of Meth for 24 hours. Calibration bar: 10 μm.  
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Figure 21. Effects of Meth on GFAP expression in primary cortical astrocytes cultures. 
(A) Representative photomicrographs of purified astrocytes cells cultures treated w ith 10 μM or 100 
μM of Meth for 24 hours. (B) Quantification of GFAP (red) intensity shows statistically significant 
decrease of GFAP expression on astrocytes treated w ith Meth 10 μM and 100 μM compared w ith 
untreated cells (control). Results are expressed as mean ± SEM of three independent experiments. 
Values displayed were normalized in relation to the control group. Statistical significant differences 
are signed as **p< 0.01 compared w ith control.  Calibration bar: 10 μm.  
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4.4 Conditioned medium (CM) of Meth-treated astrocytes promotes 
microglial cell activation 
In order to determine whether CM of astrocytes (ACM) treated with Meth 
can activate microglial cells, we analysed activation hallmarks, such as, 
phagocytic efficiency, iNOS expression and ROS production. 
As shown in figure 22, ACM significantly increased phagocytic efficiency 
suggesting an activated profile of microglial cells. Then, we also evaluated iNOS 
expression and our results show that CM of astrocytes treated with Meth 100 μM 
significantly increased iNOS expression in microglial cells (Fig. 23). Moreover, we 
also observed that CM of astrocytes treated with Meth significantly enhanced ROS 
production by cultured microglial (Fig. 24). Taken together, these results clearly 
show that Meth induces indirect microglial cell activation, mediated in this case 
by astrocytes. Here, one can clearly advocate that soluble factors released by 
astrocytes, in presence of Meth, would play an essential role in microglial cell 
activation.  
In order to have a hint of which factor would regulate this ACM-mediated 
microglial cell activation, we evaluated the expression of pro-inflammatory 
cytokines, such as TNF, IL-1β and IL-6 that were previously reported to be 
released from astrocytes (Lau and Yu 2001) and could potentially lead to the 
microglia activation we observed. Therefore, we analysed the mRNA expression 
levels of TNF, IL-1β and IL-6 in astrocytes treated with 100μM Meth for 24 hours. 
However, the mRNA levels of these cytokines were so low in cultured primary 
astrocytes that they could not detect by quantitative PCR, even in the presence of 
Meth. These data indicate that these cytokines were not directly responsible for 
microglial cell activation. 
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Figure 22. CM of ast rocytes exposed to Meth increases the phagocytosis in microglial 
cells. (A) Representative photomicrographs of purified microglial cells cultures t reated w ith CM of 
astrocytes treated with 100μM of Meth for 24 hours stained for IBA-1 (red) (B) Quantification of 
phagocytic efficiency shows a significant increase of phagocytosis on cells treated w ith CM of 
astrocytes incubated w ith 100μM of Meth compared w ith control. Results are expressed as mean ± 
SEM of three independent experiments. Values displayed were normalized in relation to the control 
group. Statistical significant differences are signed as *p<0.05, compared w ith control. Calibration 
bar: 10 μm.  
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Figure 23. CM of ast rocytes exposed to Meth increases iNOS expression in primary 
cortical microglial cells.  (A) Representative photomicrographs of purified microglial cells cultures 
treated w ith CM of astrocytes treated with 100μM of Meth for 24 hours (B) Quantification of iNOS 
(red) expression shows a significant increase of iNOS on cells treated with CM of astrocytes 
incubated w ith 100μM of Meth compared w ith control. Results are expressed as mean ± SEM of 
three independent experiments. Values displayed were normalized in relation to the control group. 
Statistical significant differences are signed as *p<0.05, compared w ith control. Calibration bar: 10 
μm.  
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Figure 24. CM of ast rocytes exposed to Meth increases ROS production in microglial 
cells. (A) Representative photomicrographs of purified cortical microglial cells cultures treated w ith 
CM of astrocytes treated with Meth for 24 hours stained w ith CellRox® (green) to assess ROS 
production. (B) Quantification of CellRox® expression shows a significant increase of ROS 
production on microglia treated w ith CM of astrocytes incubated w ith Meth 100 μM compared w ith 
control. Results are expressed as mean ± SEM of three independent experiments. Values displayed 
were normalized in relation to the control group. Statistical significant differences are signed as 
**p<0.01, compared w ith control. Calibration bar: 10 μm  
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5 Discussion 
In this work we show that Meth did not induce, directly, neither to a pro-
inflammatory nor to an anti-inflammatory signature in primary purified microglial 
cells. We also observed that Meth can only induce microglial cells activation 
indirectly, when astrocytes were challenge with this drug and the conditioned 
medium was administrated to microglial cells. Thus, we can accomplish that 
astrocytes act as inductors of microglia activation. 
 
5.1 Methamphetamine and Microglia activation: 
It has been previously established that Meth induces microglia activation in 
in vivo models (LaVoie, Card et al. 2004, Thomas, Walker et al. 2004, Thomas and 
Kuhn 2005) and also in brain of human addicts (Sekine, Ouchi et al. 2008). 
Regarding in vitro models, there is much less evidence of Meth-induced microglia 
activation, but it was demonstrated in HAPI microglial cell lines that high doses of 
Meth induce pro-inflammatory cytokines mRNA expression (Tocharus, Khonthun 
et al. 2010). However, this result is not directly comparable to our work, since 
they worked with immortalyzed cells exposed to high amounts of Meth. Overall, 
at the best of our knowledge, this was the first time that the Meth effects on 
microglial activation was evaluated in primary purified microglial cells with 
physiologic concentrations of Meth (Fornai, Lenzi et al. 2007) And, in these 
conditions, we verified that Meth did not directly activate microglial cells towards 
a pro-inflammatory profile. We analysed the phagocytic activity, iNOS expression, 
reactive oxygen species and pro-inflammatory cytokines mRNAs levels as 
hallmarks of pro-inflammatory activation. Surprisingly, we observed that Meth did 
not increase any of these parameters, which strongly suggest that Meth did not 
induce activation of primary purified microglia.  
Accumulated evidence has involved overproduction of nitric oxide (NO) in 
methamphetamine (Meth)-induced neurotoxicity (Sheng, Cerruti et al. 1996). 
Several studies have demonstrated that the use of NO synthase blockers can 
provide significant attenuation of the toxic effects of Meth in both in vitro and in 
vivo (Di Monte, Royland et al. 1996, Sheng, Cerruti et al. 1996, Ali and Itzhak 
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1998). However, in the present study, exposure of microglial cells to Meth did not 
result in increased production of NO (accessed indirectly through expression of 
iNOS) which corroborates our findings showing that, in microglia cells, Meth is 
not able to increase iNOS expression in a direct way . 
Furthermore, it has also been proposed that pro-inflammatory cytokines 
are involved in the toxic effects of Meth in CNS. Studies demonstrated that Meth 
increased levels of IL-1β mRNA in the hypothalamus (Yamaguchi, Kuraishi et al. 
1991, Halladay, Kusnecov et al. 2003), and TNF mRNA in the mouse brain (Flora, 
Lee et al. 2002). Moreover, it was described that TNF-α and IL-6 mRNA levels 
rapidly increase in the hippocampus of Meth-exposed mice (Gonçalves, Baptista et 
al. 2010). Furthermore, Meth–induced neurotoxic effects were attenuated in mice 
with a null mutation for IL-6, suggesting that this cytokine might be an important 
component of the toxic cascade triggered by this psychostimulant (Ladenheim, 
Krasnova et al. 2000). In our work, we evaluated Meth effect in pro-inflammatory 
cytokines through mRNA levels in primary microglial cell cultures at 3 and 24 
hours post treatment. Our results showed that Meth does not induce significant 
changes in the mRNA levels in none of the analysed pro-inflammatory markers (IL-
1, IL-6 and TNF). Based on these results it is possible to conclude that in the 
presence of Meth isolated microglial cells do not acquire an activated signature, 
which goes against previous results described by other authors (Tocharus, 
Chongthammakun et al. 2008, Tocharus, Khonthun et al. 2010). As already 
mentioned, these differences can be related to the use of microglial immortalized 
cell lines, and may also be attributed to the higher Meth doses used in those 
studies, which do not seem to transcribe a physiologic microglia response. 
Another relevant aspect is that many of the existing studies reporting 
Meth-induced activation of microglia were conducted in vivo (LaVoie, Card et al. 
2004, Sekine, Ouchi et al. 2008, Robson, Turner et al. 2014) where many other 
CNS cells are also affected by Meth exposure, which may obviously influence or 
exacerbate the microglial response. Importantly, from these studies in yet not 
possible to difference between the acute and chronic effects of Meth at the 
microglial level. Therefore, further studies will be needed to clarify this profile. 
 
Based on the results presented above it is possible to conclude that Meth 
does not induce a pro-inflammatory signature in microglial cells, so, we decided 
to evaluate the hypothesis that, in presence of Meth, microglia could acquire an 
anti-inflammatory profile. To clarify this we evaluated the expression of anti-
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inflammatory markers in microglial cells such as Arginase 1, TGF-β and IL-10. 
Arginase 1 increased expressed in microglial cells is associated to an anti-
inflammatory state (Michelucci, Heurtaux et al. 2009, Goldmann and Prinz 2013). 
It is known that arginase 1 competes with iNOS to the use of L-arginine as a 
substrate leading to reduced inhibit NO production (Chang, Liao et al. 1998). In 
the present study, we did not observe any significant changes in Arginase 1 
expression in presence of Meth, which does not favor the hypothesis that Meth 
could induce an anti-inflammatory state in microglial cells. 
IL-10 and TGF-β are key anti-inflammatory markers that modulate 
astrocytes and microglia activation (Ridet, Privat et al. 1997, Hanisch 2002, 
Kremlev and Palmer 2005, Norden, Fenn et al. 2014). Studies have demonstrate 
that administration of IL-10 suppresses LPS-induced IL-1β expression in the 
hippocampus (Lynch, Walsh et al. 2004), while in IL-10 deficient mice, LPS 
challenge lead to increased and prolonged neuroinflammation (Richwine, 
Sparkman et al. 2009). TGF-β is known to inhibit pro-inflammatory cytokines and 
nitric oxide (NO) production by activated microglia (Suzumura, Sawada et al. 
1993, Orellana, Montero et al. 2013). Our results do not show increased mRNA 
levels of any of these anti-inflammatory markers in microglial cells exposed to 
Meth. Together with the Arginase 1 results, these findings indicate that microglia 
cells do not acquire an anti-inflammatory signature in presence of Meth. 
As Meth was not able to act on the microglial activation state directly, and 
in vivo studies clearly show an activation of these cells after Meth administration, 
it seems reasonable to suppose that this in vivo activation may result from the 
interplay with other cellular players such as the astrocytes or different neuronal 
types. 
 
5.2 Methamphetamine and Astrocyte activation: 
Both in vivo and in vitro studies reported astrogliosis in the presence of 
Meth (Narita, Miyatake et al. 2006, Robson, Turner et al. 2014).  In this activated 
stage, astrocytes can release many inflammatory factors that may influence 
microglial cells. It was already demonstrated that repeated in vivo Meth treatment 
induced a robust activation of astrocytes as shown by significant increase in glial 
fibrillary acidic protein (GFAP) levels in several mice brain regions such as the 
49 
cingulate cortex, nucleus accumbens, hippocampus (Gonçalves, Baptista et al. 
2010) and the striatum (Narita, Miyatake et al. 2005, Zhu, Xu et al. 2005). GFAP 
was also shown to be increased in the brain astrocytes of human Meth-addicts 
(Kitamura, Takeichi et al. 2010). 
Thus, we accessed the activation of astrocytes after Meth exposure, by 
analyzing the stress fibers, GFAP and iNOS expression in these cells. As reported, 
we did not observe any Meth-induce significant increase in the expression of 
iNOS, GFAP or stress fibers when compared to the control. Therefore, as observed 
for microglial cells, Meth exposure does not seem to be able to directly activate 
primary astrocytes. Other authors however, have reported increased GFAP 
expression in astrocytes exposed to similar concentrations of Meth for a period 
of 3 days (Narita, Miyatake et al. 2005). Another in vitro study also reported Meth-
increased expression of GFAP when using co-cultures of neuron-glia, which does 
not allow to evaluate Meth effects on isolate astrocytes (Narita, Miyatake et al. 
2005, Narita, Miyatake et al. 2006).  Therefore, although we did not observe an 
activation of astrocytes at 24h, it is possible that longer Meth exposure periods 
could lead to a different result. 
 
5.3 Astrocytes and microglia cross-talk under Meth exposure: 
The bidirectional communication between neurons and astrocytes through 
the so-called gliotransmitters (such as glutamate, ATP, and D-serine) has been 
shown to modulate synaptic transmission and plasticity through several 
mechanisms (Araque, Carmignoto et al. 2014). Glutamatergic signalling in 
particular has been implicated in the modulation of drug-seeking behaviour 
(Reissner, Gipson et al. 2014). Increased levels of glutamate are well known to 
lead to sustained Ca
2+
 influx and initiating a cascade-like effect that leads to cell 
death (Dong, Wang et al. 2009). In the process, there is substantial ROS formation 
and consequently increased oxidative damage. Increased glutamate release is 
often associated to neuroinflammation (Tzschentke and Schmidt 2003).  
In vitro studies showed that astrocytes could cooperate with microglia to 
prevent excessive inflammatory responses in the brain, as it was demonstrated 
that microglia treated with astrocyte conditioned medium (ACM) reduce iNOS and 
ROS production by an increased expression of microglial antioxidant enzymes 
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(Min, Yang et al. 2006). Furthermore, it was also reported that in microglia 
treated with ACM suppressed interferon-gamma (IFN-ϒ)-induced ROS production, 
leading to reduced iNOS expression and NO release (Min, Yang et al. 2006, Shih, 
Fernandes et al. 2006). However, it was also reported that microglial release of 
TNF reduces the activity of glutamate transporters in astrocytes, further 
contributing to a hyperglutamate state (Zou and Crews 2005). Although activation 
of microglia and astrocytes are normal homeostatic mechanisms in brain injury, 
excessive neuroinflammation may result in further damage.  
 
 As such, although Meth did not induce astrocyte activation, we used the 
conditioned medium of Meth treated astrocytes to incubate microglial cells. We 
observed that ACM treated with Meth significantly increase phagocytic activity, 
iNOS expression and ROS production in primary microglia cell cultures. These 
results strongly suggest that, in presence of CM of astrocytes treated with Meth, 
microglial cells acquire an activated signature. Although Meth did not directly 
activate astrocytes, this compound induced astrocytes to release soluble factors 
that directly modulate microglia activation.  
In order to isolate possible astrocyte-released factors involved in triggering 
microglial activation under Meth exposure , we analyzed the production, in 
astrocytes, of pro-inflammatory cytokines such as IL-6, TNF and IL-1β (Lau and Yu 
2001, Hanisch 2002). However the mRNA levels of such cytokines were too low to 
be detected through quantitative PCR, indicating that further studies are needed 
to reliably understand the concrete role of these cytokines (IL-6, TNF and IL-1β) in 
microglia activation induced by ACM. 
Another possible mediator in the astrocyte-microglia cross-talk is the 
excitotoxic release of glutamate. Further studies will be necessary to confirm this 
hypothesis. 
In conclusion, Meth per se does not induce a pro-inflammatory or an anti-
inflammatory signature in microglial cells nor increase reactivity in astrocytes. 
Under Meth exposure, microglia activation appears to be mediated by astrocyte-
released factors, however at this point is not possible to exclude a possible role 
for other cellular players, as the different neuronal types. Mainly, dopaminergic 
and glutamatergic neurons, classic targets of Meth, may also contribute to the 
activation of microglia. 
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6. Conclusion 
In this work we investigated the effects of Meth on primary microglial cells 
cultures. We observed that Meth per se did not shift microglial cells neither to a 
pro-inflammatory nor anti-inflammatory signature. 
 Also, we found that Meth per se has not induced an activated state on 
astrocytes in culture. However, microglia activation appears to be mediated by 
conditioned medium of astrocytes treated with Meth. 
The results described above clearly show that Meth induces indirectly 
microglial activation and astrocytes appear to be a vehicle for this activation, 
however it is important to not rule out the hypothesis that another CNS cell can 
also influence microglial activation induced by Meth. 
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